Tenderwize
Back to tender search

Open house discount contracts for Metformin/Dapagliflozin

Techniker Krankenkasse·Hamburg, Germany·Deadline Jul 30, 2027 · 346 days left·Open·Supplies
Structured notice only
Original notice title

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-20 - Metformin/Dapagliflozin (Wirkstoffkombination)

60/100

Opportunity Score

Needs reviewLow complexity
SuppliesOpen
Why this score?

Opportunity

60 / 100

Complexity

30 / 100

Risk factors

No estimated contract value or volume is provided, making it impossible to assess potential revenue.

Contract automatically ends upon patent expiry or loss of market exclusivity, which could occur before the planned end...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 2 lots
  • Duration until Jul 2027
  • Conclusion of discount agreements (Rabattverträge) for the fixed combination Metformin/Dapagliflozin
  • Contract term of maximum 24 months starting 01.08.2025, ending no later than 31.07.2027
Show full summary

Open House Originale procedure by Techniker Krankenkasse (TK) for discount agreements on the fixed combination Metformin/Dapagliflozin (active substance combination) under §130c SGB V. The procedure is open to all eligible pharmaceutical entrepreneurs offering this drug. Contracts have uniform conditions, no exclusivity, and a maximum term of 24 months (01.08.2025 to 31.07.2027), subject to early termination upon patent expiry. Joining is possible at any time during the contract period. Submission is via email with qualified electronic signature or by post.

Risks

No estimated contract value or volume is provided, making it impossible to assess potential revenue.

Contract automatically ends upon patent expiry or loss of market exclusivity, which could occur before the planned end...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Must be a pharmaceutical entrepreneur (Pharmazeutischer Unternehmer) as defined in §4 Abs. 18 AMG
  • Must have a valid marketing authorization for the specific drug or equivalent right to place it on the market
  • Seat must be in Germany, another EU member state, or an EEA state

Requirements may be incomplete.

Buyer

Location

Hamburg, DEU

Identifier

992-80116-93

Activity

Health

Lots (2)

LOT-0001

No Lot Division

Discount agreement for the fixed combination Metformin/Dapagliflozin. Open to all eligible pharmaceutical entrepreneurs. Uniform conditions, no exclusivity. Contract term max 24 months from 01.08.2025, ending 31.07.2027. Joining possible anytime.

SuppliesEU fundedElectronic submission

Location

DE600, Germany

Duration

Jul 2025 - Jul 2027

Category

Pharmaceutical products

LOT-0002

No Lot Split

Discount agreement for the fixed combination Metformin/Dapagliflozin. Open to all eligible pharmaceutical entrepreneurs. Uniform conditions, no exclusivity. Contract term max 24 months from 01.08.2025, ending 31.07.2027. Joining possible anytime.

SuppliesEU fundedElectronic submission

Location

DE600, Germany

Duration

Jul 2025 - Jul 2027

Category

Pharmaceutical products

Procurement Details

Publication date
19 May 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
324600-2025

Documents (1)

Similar tenders